Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23754183 | 0.80 | KCNJ1 (0.46) | KCNJ1CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL17645818 | 0.75 | KCNJ1 (0.45) | KCNJ1CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2600020 | 0.74 | TRIM24 (0.53) | KCNJ1CHRNB2CHRNA4MAPT | |
| SCHEMBL23769143 | 0.73 | KCNJ1 (0.46) | KCNJ1CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL23408618 | 0.73 | ABL1 (0.45) | KCNJ1MAPT | |
| SCHEMBL23769146 | 0.73 | HRH3 (0.40) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL23408619 | 0.73 | ABL1 (0.45) | KCNJ1MAPT | |
| SCHEMBL12780921 | 0.72 | ALDH1A1 (0.55) | KCNJ1CHRNB2CHRNA4MAPTRAB9A | |
| SCHEMBL23754172 | 0.72 | NPC1 (0.35) | RAB9A | |
| SCHEMBL17645891 | 0.72 | KCNJ1 (0.42) | KCNJ1CHRNB4CHRNA3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| WO-2021160718-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KCNJ1 675/4885CHRNB4 3566/4885CHRNA3 3108/4885 |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KCNJ1 675/4885CHRNB4 3566/4885CHRNA3 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.